Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.

Patel MR, Dash A, Jacobson BA, Ji Y, Baumann D, Ismail K, Kratzke RA.

Cancer Gene Ther. 2019 Nov;26(11-12):411-418. doi: 10.1038/s41417-018-0074-6. Epub 2019 Jan 9.

PMID:
30622322
2.

Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.

Alharbi AF, Kratzke RA, D'Cunha J, Maddaus MA, Sanghavi K, Kirstein MN.

Cancer Chemother Pharmacol. 2019 Feb;83(2):387-391. doi: 10.1007/s00280-018-3757-7. Epub 2018 Dec 12.

3.

Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancer.

De A, Jacobson BA, Peterson MS, Stelzner ME, Jay-Dixon J, Kratzke MG, Patel MR, Bitterman PB, Kratzke RA.

Cancer Gene Ther. 2019 May;26(5-6):157-165. doi: 10.1038/s41417-018-0058-6. Epub 2018 Nov 12.

PMID:
30420719
4.

Meet the new boss: lung cancer staging.

Begnaud A, Kratzke RA.

J Thorac Dis. 2018 Mar;10(3):1329-1331. doi: 10.21037/jtd.2018.03.89. No abstract available.

5.

4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.

De A, Jacobson BA, Peterson MS, Jay-Dixon J, Kratzke MG, Sadiq AA, Patel MR, Kratzke RA.

Invest New Drugs. 2018 Apr;36(2):217-229. doi: 10.1007/s10637-017-0535-z. Epub 2017 Nov 8.

PMID:
29116477
6.

Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma.

Jacobson BA, Sadiq AA, Tang S, Jay-Dixon J, Patel MR, Drees J, Sorenson BS, Russell SJ, Kratzke RA.

Oncotarget. 2017 Jun 27;8(38):63096-63109. doi: 10.18632/oncotarget.18656. eCollection 2017 Sep 8.

7.

Oncolytic Viral Therapy for Mesothelioma.

Pease DF, Kratzke RA.

Front Oncol. 2017 Aug 24;7:179. doi: 10.3389/fonc.2017.00179. eCollection 2017. Review.

8.

Targeting eukaryotic protein translation in mesothelioma.

Kratzke RA.

Transl Lung Cancer Res. 2017 Jun;6(3):343-349. doi: 10.21037/tlcr.2017.06.07. Review.

9.

Novel oncolytic viral therapies in patients with thoracic malignancies.

Ahmad Z, Kratzke RA.

Oncolytic Virother. 2016 Dec 21;6:1-9. doi: 10.2147/OV.S116012. eCollection 2017. Review.

10.

Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance).

Martin LW, D'Cunha J, Wang X, Herzan D, Gu L, Abraham N, Demmy TL, Detterbeck FC, Groth SS, Harpole DH, Krasna MJ, Kernstine K, Kohman LJ, Patterson GA, Sugarbaker DJ, Vollmer RT, Maddaus MA, Kratzke RA.

J Clin Oncol. 2016 May 1;34(13):1484-91. doi: 10.1200/JCO.2015.63.4543. Epub 2016 Feb 29.

11.

Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.

Patel MR, Jacobson BA, Ji Y, Drees J, Tang S, Xiong K, Wang H, Prigge JE, Dash AS, Kratzke AK, Mesev E, Etchison R, Federspiel MJ, Russell SJ, Kratzke RA.

Oncotarget. 2015 Oct 20;6(32):33165-77. doi: 10.18632/oncotarget.5320.

12.

Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.

Ferguson DM, Jacobson BA, Jay-Dixon J, Patel MR, Kratzke RA, Raza A.

Anticancer Res. 2015 Oct;35(10):5211-7.

PMID:
26408679
13.

Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells.

Thumma SC, Jacobson BA, Patel MR, Konicek BW, Franklin MJ, Jay-Dixon J, Sadiq A, De A, Graff JR, Kratzke RA.

Cancer Gene Ther. 2015 Aug;22(8):396-401. doi: 10.1038/cgt.2015.34. Epub 2015 Jul 31.

PMID:
26227824
14.

Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesothelioma.

Jacobson BA, Chen EZ, Tang S, Belgum HS, McCauley JA, Evenson KA, Etchison RG, Jay-Dixon J, Patel MR, Raza A, Saluja AK, D'Cunha J, Kratzke RA.

Genes Cancer. 2015 Mar;6(3-4):144-52.

15.

Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.

Patel MR, Jacobson BA, Belgum H, Raza A, Sadiq A, Drees J, Wang H, Jay-Dixon J, Etchison R, Federspiel MJ, Russell SJ, Kratzke RA.

J Thorac Oncol. 2014 Aug;9(8):1101-10. doi: 10.1097/JTO.0000000000000214.

16.

Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells.

Chen EZ, Jacobson BA, Patel MR, Okon AM, Li S, Xiong K, Vaidya AJ, Bitterman PB, Wagner CR, Kratzke RA.

Invest New Drugs. 2014 Aug;32(4):598-603. doi: 10.1007/s10637-014-0076-7. Epub 2014 Apr 9.

PMID:
24711125
17.

Epigenetics of lung cancer.

Langevin SM, Kratzke RA, Kelsey KT.

Transl Res. 2015 Jan;165(1):74-90. doi: 10.1016/j.trsl.2014.03.001. Epub 2014 Mar 12. Review.

18.

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.

Khatri A, Williams BW, Fisher J, Brundage RC, Gurvich VJ, Lis LG, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK, Kirstein MN.

Br J Cancer. 2014 Jan 21;110(2):304-12. doi: 10.1038/bjc.2013.738. Epub 2013 Dec 3.

19.

Response.

Xu Y, Zheng M, Khuong A, Merritt RE, Shrager JB, Wakelee HA, Kratzke RA, Hoang CD.

Chest. 2013 Dec;144(6):1971-1972. doi: 10.1378/chest.13-1931. No abstract available.

PMID:
24297135
20.

Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide.

Jacobson BA, Thumma SC, Jay-Dixon J, Patel MR, Dubear Kroening K, Kratzke MG, Etchison RG, Konicek BW, Graff JR, Kratzke RA.

PLoS One. 2013 Nov 18;8(11):e81669. doi: 10.1371/journal.pone.0081669. eCollection 2013.

21.

Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.

Patel MR, Jay-Dixon J, Sadiq AA, Jacobson BA, Kratzke RA.

J Thorac Oncol. 2013 Sep;8(9):1142-7. doi: 10.1097/JTO.0b013e31829ce963.

22.

miR-1 induces growth arrest and apoptosis in malignant mesothelioma.

Xu Y, Zheng M, Merritt RE, Shrager JB, Wakelee HA, Kratzke RA, Hoang CD.

Chest. 2013 Nov;144(5):1632-1643. doi: 10.1378/chest.12-2770.

23.

Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer.

Powell SF, Beitinjaneh A, Tessema M, Bliss RL, Kratzke RA, Leach J, Dudek AZ.

Clin Lung Cancer. 2013 Sep;14(5):495-501. doi: 10.1016/j.cllc.2013.04.009. Epub 2013 Jun 28.

24.

Oncolytic virus therapy for cancer: the first wave of translational clinical trials.

Patel MR, Kratzke RA.

Transl Res. 2013 Apr;161(4):355-64. doi: 10.1016/j.trsl.2012.12.010. Epub 2013 Jan 10. Review.

PMID:
23313629
25.

Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.

Mitra AK, Kirstein MN, Khatri A, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK.

Pharmacogenomics. 2012 Jul;13(9):1009-21. doi: 10.2217/pgs.12.81.

PMID:
22838949
26.

Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer.

Edelman MJ, Hodgson L, Wang X, Kratzke RA, Vokes EE.

J Clin Oncol. 2012 Jun 1;30(16):2019-20; author reply 2020. doi: 10.1200/JCO.2011.41.4581. Epub 2012 Apr 2. No abstract available.

27.

Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.

Dudek AZ, Pang H, Kratzke RA, Otterson GA, Hodgson L, Vokes EE, Kindler HL; Cancer and Leukemia Group B.

J Thorac Oncol. 2012 Apr;7(4):755-9. doi: 10.1097/JTO.0b013e318248242c.

28.

Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation.

Patel MR, Sadiq AA, Jay-Dixon J, Jirakulaporn T, Jacobson BA, Farassati F, Bitterman PB, Kratzke RA.

Int J Oncol. 2012 Feb;40(2):577-82. doi: 10.3892/ijo.2011.1252. Epub 2011 Nov 4.

29.

Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.

Fujioka N, Nguyen J, Chen C, Li Y, Pasrija T, Niehans G, Johnson KN, Gupta V, Kratzke RA, Gupta K.

Anesth Analg. 2011 Dec;113(6):1353-64. doi: 10.1213/ANE.0b013e318232b35a. Epub 2011 Oct 14.

30.

Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis.

Raza A, Jacobson BA, Benoit A, Patel MR, Jay-Dixon J, Hiasa H, Ferguson DM, Kratzke RA.

Invest New Drugs. 2012 Aug;30(4):1443-8. doi: 10.1007/s10637-011-9720-7. Epub 2011 Jul 26.

PMID:
21789510
31.

Expression and phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 in B-cell lymphomas and reactive lymphoid tissues.

Kodali D, Rawal A, Ninan MJ, Patel MR, Mesa H, Knapp D, Schnitzer B, Kratzke RA, Gupta P.

Arch Pathol Lab Med. 2011 Mar;135(3):365-71. doi: 10.1043/2009-0759-OA.1.

PMID:
21366462
32.

Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model.

Mitra R, Lee J, Jo J, Milani M, McClintick JN, Edenberg HJ, Kesler KA, Rieger KM, Badve S, Cummings OW, Mohiuddin A, Thomas DG, Luo X, Juliar BE, Li L, Mesaros C, Blair IA, Srirangam A, Kratzke RA, McDonald CJ, Kim J, Potter DA.

Clin Cancer Res. 2011 May 1;17(9):2934-46. doi: 10.1158/1078-0432.CCR-10-1803. Epub 2011 Jan 17.

33.

Long-term survival of a patient with squamous cell carcinoma harboring NUT gene rearrangement.

Fujioka N, French CA, Cameron MJ, Kratzke RA.

J Thorac Oncol. 2010 Oct;5(10):1704-5. doi: 10.1097/JTO.0b013e3181ebaa20. No abstract available.

34.

Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy.

Li H, Peng KW, Dingli D, Kratzke RA, Russell SJ.

Cancer Gene Ther. 2010 Aug;17(8):550-8. doi: 10.1038/cgt.2010.10. Epub 2010 Apr 9.

35.

A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).

Miller AA, Pang H, Hodgson L, Ramnath N, Otterson GA, Kelley MJ, Kratzke RA, Vokes EE; Cancer and Leukemia Group B (CALGB).

J Thorac Oncol. 2010 Mar;5(3):380-4. doi: 10.1097/JTO.0b013e3181cee36e.

36.

p16(INK4a) Peptide mimetics identified via virtual screening.

Klein MA, Mayo KH, Kratzke RA.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):403-5. doi: 10.1016/j.bmcl.2009.10.046. Epub 2009 Oct 15.

PMID:
19914831
37.

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.

Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA.

Br J Cancer. 2009 Oct 6;101(7):1114-23. doi: 10.1038/sj.bjc.6605297.

38.

Survival of patients with distal esophageal and gastric cardia tumors: a population-based analysis of gastroesophageal junction carcinomas.

Whitson BA, Groth SS, Li Z, Kratzke RA, Maddaus MA.

J Thorac Cardiovasc Surg. 2010 Jan;139(1):43-8. doi: 10.1016/j.jtcvs.2009.04.011. Epub 2009 Jun 13.

39.

Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer.

Dudek AZ, Lesniewski-Kmak K, Larson T, Dragnev K, Isaksson R, Gupta V, Maddaus MA, Kratzke RA.

J Thorac Oncol. 2009 Aug;4(8):969-75. doi: 10.1097/JTO.0b013e3181add877.

40.

Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma.

Jacobson BA, De A, Kratzke MG, Patel MR, Jay-Dixon J, Whitson BA, Sadiq AA, Bitterman PB, Polunovsky VA, Kratzke RA.

Br J Cancer. 2009 Aug 4;101(3):424-31. doi: 10.1038/sj.bjc.6605184. Epub 2009 Jul 14.

41.

Cap-dependent translation blockade and fixed dose-rate gemcitabine: interaction in an in vitro bioreactor system.

Williams BW, Chang JJ, Chi RM, Marker PH, Frethem CD, Le CT, Kratzke RA, Kirstein MN.

Cancer Lett. 2009 Oct 18;284(1):37-46. doi: 10.1016/j.canlet.2009.04.006. Epub 2009 May 12.

PMID:
19442436
42.

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor.

Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, Franklin M, Kratzke RA, Greeno EW, Kumar P.

Br J Cancer. 2009 May 5;100(9):1379-84. doi: 10.1038/sj.bjc.6605043.

43.

Lung cancer and lung transplantation: a review.

Mathew J, Kratzke RA.

J Thorac Oncol. 2009 Jun;4(6):753-60. doi: 10.1097/JTO.0b013e31819afdd9. Review.

44.

Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II.

Sadiq AA, Patel MR, Jacobson BA, Escobedo M, Ellis K, Oppegard LM, Hiasa H, Kratzke RA.

Invest New Drugs. 2010 Feb;28(1):20-5. doi: 10.1007/s10637-008-9209-1. Epub 2009 Jan 10.

45.

Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity.

Whitson BA, D'Cunha J, Andrade RS, Kelly RF, Groth SS, Wu B, Miller JS, Kratzke RA, Maddaus MA.

Ann Thorac Surg. 2008 Dec;86(6):1735-44. doi: 10.1016/j.athoracsur.2008.07.001.

PMID:
19021967
46.

Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity.

Yamoutpour F, Bodempudi V, Park SE, Pan W, Mauzy MJ, Kratzke RA, Dudek A, Potter DA, Woo RA, O'Rourke DM, Tindall DJ, Farassati F.

Mol Cancer Ther. 2008 Nov;7(11):3586-97. doi: 10.1158/1535-7163.MCT-08-0653.

47.

Minimally invasive versus open Roux-en-Y gastric bypass: effect on immune effector cells.

Whitson BA, D'Cunha J, Hoang CD, Wu B, Ikramuddin S, Buchwald H, Panoskaltsis-Mortari A, Kratzke RA, Miller JS, Maddaus MA.

Surg Obes Relat Dis. 2009 Mar-Apr;5(2):181-93. doi: 10.1016/j.soard.2008.08.019. Epub 2008 Aug 30.

PMID:
18996756
48.

Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide.

Frizelle SP, Kratzke MG, Carreon RR, Engel SC, Youngquist L, Klein MA, Fourre L, Shekels LL, Kratzke RA.

Anticancer Res. 2008 Jan-Feb;28(1A):1-7.

49.

Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.

Kratzke RA, Wang X, Wong L, Kratzke MG, Green MR, Vokes EE, Vogelzang NJ, Kindler HL, Kern JA; Cancer and Leukemia Group B.

J Thorac Oncol. 2008 Apr;3(4):417-21. doi: 10.1097/JTO.0b013e318168da0a.

50.

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ.

J Clin Oncol. 2008 Feb 20;26(6):848-55. doi: 10.1200/JCO.2007.13.8081.

PMID:
18281656

Supplemental Content

Loading ...
Support Center